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Abstrakt
Programovatelné endonukleázy jsou proteiny schopné rozpoznat specifické sekvence 
nukleotidů a následně v rozpoznané sekvenci štěpit obě vlákna DNA. Zinc-finger nukleázy 
jsou široce využívaným nástrojem v genomové editaci, metodě zavádění změn do genomů 
buněčných liní nebo celých organismů za účelem studia funkce genů. Nedávno se objevily 
nové typy programovatelných endonukleáz v podobě transcription activator-like effector 
(TALE) nukleáz a CRISPR/Cas systému. Tyto systémy se od sebe liší z pohledu mecha-
nizmu funkce, dostupnosti, selektivity, frekvence off-targetů a cytotoxicity. V této práci 
zinc-finger nukleázy, TALE nukleázy a CRISPR/Cas systém porovnáváme a zkoumáme 
jejich aktuální a možné budoucí využití v široké oblasti výzkumu, který sahá od vývoje 
geneticky modifikovaných organismů až po genovou terapii.
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Abstract
Programmable endonucleases are engineered proteins that recognize specific nucleotide 
sequences and that are capable of introducing double-strand breaks within these sequenc-
es. Zinc-finger nucleases have been used extensively as a tool in genome editing, the prac-
tice of introducing changes into genomes of cell lines or whole organisms as a way to study 
gene function. Recently, new types of programmable endonucleases have emerged in the 
form of transcription activator like effector (TALE) nucleases and the CRISPR/Cas sys-
tem. The types differ in respect to their mechanism of function, accessibility, selectivity, 
frequency of off-target cleavage and cytotoxic effects. Here, we compare zinc-finger nucle-
ases, TALENs and the CRISPR/Cas system and explore their current and possible future 
applications in a broad spectrum of research ranging from developing genetically modified 
organisms to gene therapy.
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Glossary
CRISPR  clustered regularly interspaced short palindromic repeat
DSB   double-strand break
ESC  embryonic stem cell
HR   homologous recombination
NHEJ  non-homologous end-joining
PAM   protospacer adjacent motif
RVD   repeat-variable di-residue
TALEN  transcription activator-like effector nuclease 
ZFN   zinc-finger nuclease
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1. Introduction
Genome editing (or genome engineering) is the practice of introducing specific changes 
into genomes of model organisms or cell lines. It is a widely used and tried approach to un-
derstanding gene function through alteration, removal, fusion with a reporter tag and even 
replacement with a different gene. There are numerous engineered knock-out or knock-in 
model organisms and cell lines available to researchers now, for example mouse strains 
with mutations mirroring those found in humans displaying hereditary diseases are serv-
ing as models to elucidate the molecular mechanism behind the phenotype. They provide 
valuable insight into possible therapy or disease prevention and, most importantly, help 
understand the complexity of the eukaryotic organism. Biotechnology is greatly profiting 
from the ability to introduce or remove certain traits in order to engineer expression sys-
tems for protein production or increase the agricultural yield of crops. Gene therapy also 
relies on altering the genetic make-up of patient-derived cell lines in order to use them as 
a therapeutic agent.
In order to introduce changes into the genome reliably, efficiently, and lastingly, it is 
desirable to target specific loci within the genome.  But to do this safely in for example the 
human genome (which comprises approx. 3.2 Gbp), the targeted DNA sequence has to be at 
least 16 bp in length to ensure its uniqueness within the genome. Statistically, a 16 bp long 
sequence should occur just once within a genome of the size of 416 bp (4.5 Gbp), assum-
ing the bases are randomly distributed. In comparison, type II restriction endonucleases 
generally recognize sequences only 4–8 bp in length, and their use as a means to introduce 
double-strand breaks (DSBs) on unique sites in large genomes is severely limited. 
The introduction of DSBs is a crucial step in genome editing. DSBs on genomic DNA are 
repaired by the two prevalent DNA damage repair pathways, non-homologous end-joining 
(NHEJ) and homologous recombination (HR) (Takata et al. 1998). If a DSB is repaired by 
NHEJ, this error-prone mechanism frequently leads to indels at the site of the DSB. Thus, 
if the DSB is targeted into a specific locus within an exon of a chosen gene, repair by NHEJ 
can lead to frameshift-inducing indels and therefore a truncated or absent product. Alter-
natively, larger deletions can be induced by the introduction of two DSBs flanking a longer 
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sequence, leading to deletion of the entire flanked segment. Another repair mechanism en-
dogenous to most eukaryotes is homologous recombination (HR) — it requires a template 
in the form of DNA homologous to the target site, and though it does not not need to be 
preceded by the introduction of a DSB, its frequency greatly increases if a DSB is present. 
Defined mutations can be generated by providing a template for homologous recombina-
tion (HR), and large fragments of DNA can be inserted into the genome via HR in a similar 
fashion.
Programmable endonucleases are a powerful tool that enables researchers to intro-
duce DSBs in pre-selected sequences within the genome. Zinc-finger nucleases (ZFNs) have 
been around for a few decades, but two alternatives have emerged recently and are being 
developed intensively: Transcription activator-like effector nucleases (TALENs) and the re-
cently utilized CRISPR/Cas system are becoming indispensable tools for genome editing. 
The nucleases can be engineered to recognize a specific sequence of sufficient length to be 
unique within even a large genome. Already they have enabled the development of many 
previously unattainable genetically modified animals and plants from a variety of species, 
thus aiding several fields of research. Lasting changes to the genome have a distinct advan-
tage over gene-knockdown by RNAi, since introducing changes on the DNA level rather 
than the transcriptional level prevents the targeted gene being leaky and small amounts of 
the product still being present within targeted cells (Kim et al. 2011). In addition, genome 
editing allows for reproducible and reliable results. 
Here, we examine the mechanism of function of zinc-finger nucleases, TALE nucleases 
and the CRISPR/Cas system in order to attempt a comparison of these three most widely 
used programmable endonucleases in respect to their accessibility, effectivity, off-target 
cleavage frequency and cytotoxicity. We further explore their potential as genome editing 
tools and their current and possible future applications in the generation of genetically 
modified animal models and cell lines, and their potential in biomedicine. Finally, we dis-
cuss the shortcomings of each particular method, and offer suggestions for future research.
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2. Zinc-finger nucleases (ZFNs)
The Cys2-His2 zinc-finger domain is a DNA-binding motif commonly present in mam-
malian transcription factors (Miller et al. 1985). Each domain binds a zinc ion, displays 
a ββα fold and is able to recognize and bind to a 3 bp sequence. The α-helix inserts into 
the major groove, and due to variations in the amino-acid residues present is able to rec-
ognize various combinations of base pairs within the groove (Figure 1). Naturally occur-
ring zinc-finger proteins do not recognize more than 9 bp long sequences using three do-
mains. Although the number of domains present in a zinc-finger protein can be higher, 
not more than three domains partici-
pate in the binding itself (Gupta et 
al. 2014).  Based on the structure of 
Zif268 bound to DNA obtained using 
x-ray crystallography, so-called poly-
dactyl zinc-finger proteins containing 
several zinc-finger domains linked 
together were designed, thus obtain-
ing an artificial DNA-binding domain 
capable of recognizing and binding 
longer sequences (Liu et al. 1997). 
Since the binding properties of each 
individual zinc-finger domain are not 
entirely stand-alone but rather co-
determined by the adjacent domains, 
methods that enable selection of effi-
cient zinc-finger arrays had to be im-
plemented.
Eventually, libraries of zinc-finger domains targeting 5’ GNN 3’, 5’ ANN 3’ and 
5’ CNN 3’ were constructed (Gonzalez et al. 2010). The modular assembly methods rely on 
these libraries to construct multi-finger proteins  and then using a suitable selection system 
(such as the bacterial two-hybrid system) to obtain zinc-finger constructs with high bind-
ing specificity to the intended target region. These methods treat individual zinc-fingers 
as units. Sigma-Aldrich has undertaken large-scale research into zinc-finger develope-
Figure 1. Zinc-finger nuclease architecture. (A) Strucure of 
a zinc-finger array bound to its target DNA with close-up of 
a single zinc-finger domain, showing the amino acid residues 
bound to a zinc ion and the four residues (-1, 2, 3, 6) responsible 
for contacting base pairs within the major groove. (B) A pair 
of zinc-finger nucleases (ZFNs) recognizing a target  sequence 
with the Fok1 nuclease domain bound to the C-terminal end. 
Adapted from Gaj et al. 2013.
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ment and now offers custom zinc-fingers made using their proprietary modular assembly 
technique as a commercial product (“CompoZr® Custom ZFN Service | Sigma-Aldrich” 
2014). Another assembly and selection method is the OPEN protocol (oligomerized pool 
engineering) — this combinatorial approach utilizes a limited library of individual zinc-
finger domains and takes into account which individual zinc-fingers work well together 
when assembled into arrays. The OPEN protocol claims that it should be possible to obtain 
three-finger zinc-fingers in 8 weeks, the method however does not always yield functional 
products (Maeder et al. 2009).
2.1 The FokI nuclease domain
Fusing an additional effector domain to the C-terminal end of a zinc-finger array cou-
ples the target specificity of the zinc finger array with the enzymatic activity of the selected 
effector domain (Kim et al. 1996). The type IIS FokI endonuclease derived from Flavobac-
terium okeanokoites consists of an N-terminal DNA-binding domain and a C-terminal do-
main exhibiting non-specific DNA cleavage activity (Wah et al. 1998). The cleavage domain 
retains its function when fused to a different DNA-binding protein, such as a zinc-finger 
array (Durai 2005). Dimerization of two cleavage domains is necessary for successful dou-
ble-strand breaks to occur (Bitinaite et al. 1998). A pair of such hybrid zinc-finger nucleases 
(ZFNs) is thus required for targeted DNA cleavage, the zinc-fingers binding to sequences 
flanking the desired target site, enabling the FokI nuclease domain to dimerize and cleave 
the spacer region between them.
3. Transcription activator-like effector nucleases (TALENs)
Transcription activator-like effectors (TALEs) are virulence factors belonging to mem-
bers of the bacteria genus Xanthomonas, enabling these plant pathogens to infect their 
host and induce changes beneficial to the pathogen.  Injected into the plant cell, they act as 
transcription factors within the nucleus, activating gene expression of the host (Bai et al. 
2000, Romer et al. 2007).
Members of the TALE family contain a nuclear localization signal, an acidic transcrip-
tional activation domain and a central domain. The central domain is composed of tandem 
repeats which differ in number and amino-acid composition between the members of the 
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TALE family and facilitate binding 
of the TALE to its corresponding up-
regulation target. The mechanism 
of specificity has been uncovered 
by Boch et al. by studying the Xan-
thomonas campestris pv. vesicato-
ria TAL effector AvrBs3 (Boch et al. 
2009) — its central domain contains 
tandem repeats of 34 highly con-
served amino acids, with the excep-
tion of the amino acids in positions 
12 and 13, which display a high level 
of polymorphism and are called 
repeat-variable di-residues (RVDs). 
It has been shown that these RVDs 
within a TALE repeat recognize and 
bind a single base pair within the 
target sequence of the effector fol-
lowing a simple code (Figure 2). The RVDs consisting of the amino acids NG recognize 
thymine, NI recognize adenine, HD recognize cytosine and both HN and NK recognize 
guanine with variable accuracy (Moscou and Bogdanove 2009). A known limitation as to 
the base composition of the target site is the requirement for a 5’ T preceding the first 
RVD-associated base (Gaj et al. 2013, Kim et al. 2013). Shortly after the TALE code was 
deciphered, custom engineered TALEs bound to the catalytic domain of FokI have been 
created, functioning in a similar way as the zinc-finger FokI hybrids — introducing targeted 
DSBs via a pair of transcription activator-like effector nucleases (TALENs) able to bind 
to specific sequences upstream and downstream of the intended cleavage site, mediating 
cleavage within the spacer region by enabling the FokI nuclease to dimerize (Christian et 
al. 2010). Other catalytic domains have been fused to the TALE domain, including recom-
binases (Mercer et al. 2012).
There are several methods available for designing and assembling custom TALE do-
mains. Since the individual tandem repeats within a TALE function independently, custom 
TALE domains can be designed in silico using software freely available online (Doyle et al. 
Figure 2. TALE nuclease architecture. (A) A TALE domain 
bound to its target DNA with close-up of a single subunit con-
taining the two repeat-variable di-residues (RVDs) on positions 
12 and 13. (B) Schematic drawing of a pair of TALE domains 
with the Fok1 nuclease domains bound to the C-terminal end, 
dimerizing over a spacer between the recognized sequences. 
The subunits within the TALE domain each carry a different 
RVD, allowing it to recognize the corresponding nucleotide. 
Adapted from Gaj et al. 2013.
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2012). One of them utilises the Golden Gate assembly method, allowing for simultaneous 
joining of several DNA fragments in one reaction (Cermak et al. 2011). Type IIS restric-
tion endonucleases cleave several bp upstream of the sequence they recognize, thus one 
IIS restriction endonuclease can be used to create a variety of different sticky ends in one 
reaction. A library of plasmids that carry the sequence coding for each of the four RVDs is 
required. These are further subdivided in groups that correspond to positions within the 
TALE array and if cleaved by the IIS restriction nuclease result in sticky ends that allow 
them to be ligated in the desired sequence. Thus, mixing the plasmids from the correct 
group and type of RVD, digesting and ligation allows for the assembly of the entire TALE 
domain in one reaction. Further cloning is required to add the C-terminal and N-terminal 
domains containing the nuclear localization signal and the FokI nuclease domain. Cer-
mak et al. claim that this method yields functional TALENs in five days. Another available 
method of assembly is FLASH, which has been optimized for high-throughput automation 
(Reyon et al. 2012). FLASH relies on a large library of plasmids containing pre-assembled 
multimers of TALE repeats of various length, with the first repeat bound to a biotin marker 
that adheres to magnetic beads coated with streptavidin. Another recently developed high- 
throughput method uses ligation-independent cloning to assemble the TALE repeats via 
long single-strand overhangs (Schmid-Burgk et al. 2012).
4. The CRISPR/Cas system
Some species of bacteria and archaea possess an adaptive defensive mechanism against 
viral infection. Unlike the well-known restriction-modification system, the mechanism in 
question functions very similarly to RNA-interference described in eukaryotes and displays 
the capability of acting as an adaptive immune system (Wiedenheft et al. 2012). If an intra-
cellular parasite (such as a phage, but also a plasmid) invades the bacterial or archaeal host 
cell, the host cell is capable of storing short fragments of the foreign nucleic acid originating 
from the parasite in a designated locus within its own genome. These loci, termed clustered 
regularly interspaced short palindromic repeats (CRISPRs) have been discovered in several 
prokaryotic species, but their function remained unknown for several years. They consist 
of an AT-rich leader sequence, followed by direct repeats around 20–50 bp long, separated 
with spacers of varying sequence but similar length (Figure 3 A). Recently, it has been dis-
covered that the CRISPR locus gets transcribed and processed into short RNA segments 
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termed crRNAs. The previously encountered pathogen-derived nucleic acid that has been 
incorporated into the CRISPR locus each becomes part of an individual crRNA. A complex 
forms that incorporates the crRNA and uses it as a guide for cleavage of invading nucleic 
acids. Proteins required for processing and cleavage are encoded upstream of the CRISPR 
locus. These CRISPR-associated (cas) genes can vary in number and function — several 
types of CRISPR-mediated systems have been described in bacteria and archaea that differ 
in mechanism of function and contain a different set of associated cas genes. 
Different Cas proteins in the different systems described take over the steps necessary 
to ensure integration of new spacers into the CRISPR locus, transcribing and processing 
the primary transcript into crRNAs and crRNA binding, recognition and finally cleavage of 
the recognized foreign nucleic acid (Figure 3 B). The simplest family of systems is the type 
Figure 3. The CRISPR locus architecture and three types of the CRISPR/Cas system. (A) The clustered regu-
larly interspaced short palindromic repeat (CRISPR) locus contains a cas gene cassette with a variable number 
of cas genes, a leader/promoter sequence and several repeats flanking variable spacers. Foreign  (protospacer) 
DNA gets processed and inserted between repeats. (B) Mechanisms of function fall ino three types that differ 
in respect to number and types of enzymes involved in CRISPR transcription, RNA processing and   protospacer 
recognition and cleavage. Adapted from Wiedenheft et al. 2012.
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II, consisting of four different cas genes. The primary transcript composed of spacers and 
direct repeats (also called pre-crRNA) gets processed by RNase III. This cleavage is guided 
by so-called trans-acting antisense RNA (tracrRNA), which is complementary to the spac-
ers within the CRISPR locus and also encoded within the locus. Further processing yields 
crRNA which is then free to bind to Cas9, a product of one of the three cas genes present in 
the type II system. It is a large protein with multiple catalytic sites, displaying nuclease as 
well as helicase activity (Sternberg et al. 2014).
Mali et al. took the CRISPR 
type II locus from the bacteria 
Streptococcus pyogenes SF370 and 
successfully attempted to adapt 
the procaryotic immune system to 
function as a programmable tool for 
introducing double-strand breaks 
in eukaryotic chromosomes in vivo 
(Mali et al. 2013). To express trac-
rRNA and pre-crRNA (containing 
two direct repeats flanking a single 
spacer) in the eucaryotic cell, the 
U6 snRNA promotor recognized by Pol III can be used. This ensures that the transcribed 
RNA doesn’t undergo capping, polyadenylation, and subsequent export from the nucleus 
as mRNA but instead remains within the nucleus. Cas9 and RNase III genes have been 
modified to account for the codon bias difference and equipped with nuclear localization 
signals, so that the proteins are imported into the nucleus where they encounter the tracr-
RNA and pre-crRNA. Cong et al. have demonstrated that tracrRNA and pre-crRNA can be 
fused together into a chimeric guide RNA (gRNA) which is sufficient for Cas9 recognition 
and target sequence cleavage (Figure 4), thus eliminating the need for RNase III altogether 
(Cong et al. 2013). This two-component system is very flexible in terms of target sequence. 
The only requirement for Cas9 to function properly in relation to the gRNA supplied is the 
presence of a protospacer adjacent motif (PAM) located 3’ from the target sequence (which 
is referred to as the protospacer in some of the literature), in the form of 5’ NGG 3’. Mali 
et al. used 5’ GN20GG 3’ as target sequence, the 5’ G not being crucial. The PAM however 
seems to be absolutely necessary for Cas9 target sequence (protospacer) recognition.
Figure 4. The Cas9-gRNA complex recognizing its target DNA 
sequence. The protospacer adjacent motif (PAM) is located 3’ 
downstream of the genomic target sequence on the DNA strand 
complementary to the one recognized by gRNA. Adapted from 
Mali et al. 2013. 
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Mashiko et al. have succeeded in introducing indels via NHEJ in targeted loci 
(Cetn1 and Prm1) in mouse zygotes by microinjection of all  the components required for 
CRISPR/Cas-mediated cleavage (Mashiko et al. 2013). They used a circular plasmid that 
contained both the hCas9 (humanized Cas9) expression cassette and the guide-RNA 
(gRNA) expression cassette, thus demonstrating that it is not necessary to introduce Cas9 
in the form of RNA. A high efficiency has been achieved with this method: they claim to 
have obtained 40–60% knock-out animals, even several homozygotes with mutations on 
both alleles in the Cetn1 locus. Subsequent screening for hCas9 gene integration into the 
genome yielded a negative result. The CRISPR/Cas system seems to be emerging as a new 
alternative to both zinc-finger nucleases and TALE nucleases.  
5. Comparison of ZFNs, TALENs, and the CRISPR/Cas system
The programmable nucleases described before all share the main principle of function 
— recognition of a specific DNA sequence and subsequent introduction of a double-strand 
break adjacent to the recognized sequence. However, the systems differ greatly in several 
aspects: While ZFN subunits recognize 3 bp each, TALE repeats each correspond to a sin-
gle base-pair of the recognized sequence. Furthermore, neighboring ZFN subunits influ-
ence each other, while TALE repeats constitute independent units, which has implications 
for both the ease with which each type of programmable nuclease can be designed and 
assembled and the specificity with which it binds to its target sequence. While both ZFNs 
and TALENs bind in pairs, allowing the FokI nuclease domain to be activated by dimeri-
zation, the CRISPR/Cas system is based on a single RNA-binding protein that mediates 
both recognition and cleavage of the target sequence. This difference in mechanism causes 
differences in off-target cleavage activity and influences target recognition specificity. Fi-
nally, the RNA-reliant mechanism of the CRISPR/Cas system offers an advantage over 
both ZFNs and TALENs by making multiplex genome engineering possible.
5.1 Differences in respect to mechanism, accessibility, and flexibility 
While Zinc-finger nucleases (ZFNs) have proven to be reliable, their main disadvantage 
is their relatively low flexibility and cost of production. Since the individual domains rec-
ognize a 3 bp sequence, a large library of variations of ZF domains is necessary to cover all 
the possible combinations and thus allow for a desired sequence to be targeted. From this 
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library, an optimal combination has to be selected and further screening and selection is 
required to find those arrays that bind to the targeted locus. A further complication results 
from the fact that the binding of individual subunits to their target DNA is influenced by 
the adjacent subunits within the ZF array. This labor-intensive selection and screening 
process can be avoided by directly ordering custom ZFNs as a commercial product, but 
this keeps the overall cost of the method relatively high and thus renders it  inaccessible for 
many researchers with a limited budget at their disposal.
Transcription activator-like effector nucleases (TALENs) however have the distinct 
advantage of each of the individual subunit being identical with the exception of the two 
repeat-variable di-residues (RVDs) within each repeat. Since the RVDs bind specifically 
to a single base-pair within the major groove of the target DNA, only four different TALE 
subunits  are necessary. Also, as opposed to ZF subunits, TALE repeats seem to act as 
individual units. These two factors combined render TALENs more flexible in terms of 
targeting a specific sequence and essentially eliminate the necessity for binding specific-
ity and efficiency screening. There are accessible online tools available for in silico TALE 
design, which when provided with a desired target sequence will automatically assemble a 
series of possible TALE repeats, taking into account the requirement of a 5’ T preceding the 
RVD-associated base. Using one of the assembly methods described, such as the combina-
torial DNA assembly method Golden Gate, enables researchers to design, assemble, verify 
and use their own TALENs routinely with relative ease and without need to purchase pre-
assembled final products - this keeps both cost and labor-intensity of TALENs (as opposed 
to ZFNs) relatively low.
TALENs and ZFNs both rely on the same principle of function — both act as pairs of 
multi-subunit proteins containing arrays of DNA-binding domains recognizing sequences 
that flank the intended cleavage site, with FokI nuclease domains fused to the C-terminal 
ends that dimerize and cleave the target. The CRISPR/Cas system mechanism of function 
however shows similarity to RNA interference (RNAi), a pathway found in eukaryotes that 
inhibits gene expression on the mRNA level. Part of the RNAi pathway is the RISC complex, 
which incorporates siRNA complementary to the targeted mRNA which is then cleaved by 
the RISC complex (Tijsterman and Plasterk 2004). Unlike ZFNs and TALENs, where both 
target recognition and cleavage are mediated by protein subunits, the CRISPR/Cas system 
acts as a protein-RNA complex. The recently determined 3D structure of Cas9 from Strep-
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tococcus pyogenes and Actinomyces naeslundii using x-ray crystallography reveal that it 
displays a bi-lobed architecture, where one lobe contains the nuclease domains (Figure 
5). Without guide-RNA (gRNA), the enzyme adopts an auto-inhibited state in which the 
central channel that enables Cas9 to bind and cleave its target DNA remains inaccessible 
(Jinek et al. 2014).
Another distinct feature of the 
CRISPR/Cas system is the necessi-
ty of the 3 bp protospacer adjacent 
motif (PAM) located downstream 
from the target sequence (Stern-
berg et al. 2014). Sternberg et al. 
have demonstrated that this tri-nu-
cleotide sequence is unexpectedly 
crucial in all of the steps leading to 
DNA cleavage. Cas9 displays sig-
nificantly higher binding lifetimes 
to DNA containing its respective 
PAM (5’ NGG 3’) even if these are 
not preceded by a sequence com-
plementary to the Cas9-bound gRNA (also referred to as crRNA). gRNA-complementary 
sequences without an adjacent PAM do not display higher binding frequency. This indi-
cates that Cas9 uses the PAM as its primary way to seek out its target via preferentially 
binding to PAMs. The recognition is highly selective, even a single mutation (for example 
5’ NCG 3’) will prevent cleavage of the target site, even if the gRNA bound to Cas9 is fully 
complementary to the DNA sequence preceding the mutated PAM. Interestingly, though 
the Cas9-gRNA complex displays similar binding affinities with target ssDNA  and dsDNA, 
ssDNA is cleaved much slower, by several orders of magnitude. The PAM is recognized on 
the non-complementary strand to the gRNA bound to Cas9, thus ssDNA contains only 
its complement. This stringent regulation by the PAM might function as protection from 
self-cleavage of the bacterial genome within the CRISPR locus, since the spacers there are 
not followed by a PAM. It does however somewhat limit the flexibility of the CRISPR/Cas 
system as a tool for genome editing.
Figure 5. Cas9 structure and conformational change induced by 
the binding of crRNA and target DNA. (A) The channel formed by 
the nuclease lobe and the α-helical lobe envelops the RNA-DNA 
duplex. (B) Proposed model for Cas9 activation. The protospacer 
adjacent motif (PAM) is depicted as a yellow circle. Adapted from 
Jinek et al. 2014. 
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5.2 Specificity and off-target effects
A very important attribute of all the discussed programmable endonucleases is their 
selectivity with respect to target cleavage. Both ZFNs and TALENs work in pairs, their re-
spective recognized target sequences flanking a spacer (around 10 bp with ZFNs and 20 bp 
with TALENs) above which the FokI nuclease domains dimerize. The length of recognized 
sequences used as targets by individual ZFNs and TALENs is very similar, around 18 to 20 
bp (individual ZF domains recognize tri-nucleotides, thus the recognized sequence has to 
be a multiple of three). Statistically, this length is sufficient for the sequence to be unique in 
a genome of the size corresponding to the most widely used eukaryotic model organisms. 
This fact, combined with the necessity of pairs doubling the sequence targeted and the 
need of FokI nuclease domains to dimerize in order to be able to cleave acts as a safeguard 
against ZFNs and TALENs cleaving elsewhere within the genome. 
Employing bioinformatics methods in the target site selection process is another op-
tion to avoid or at least significantly reduce off-target activity. Kim et al. for example have 
utilized this strategy as a part of their effort to assemble a TALEN library spanning the hu-
man genome by screening for possible off-target sites with a suitably tailored algorithm for 
TALEN design, selecting target sequences that do not have partial homologies elsewhere 
within the genome (Kim et al. 2013). Since both designing and assembling TALENs as 
opposed to ZFNs is a more straightforward process, implementing this kind of off-target 
screening should prove more simple, even though there is no guarantee that it eliminates 
all off-target activity, since it does not account for differences in the target genome to the 
referenced genome available in the database, and other, yet undiscovered factors.
The Cas9-gRNA complex has been successfully used to target 20 bp sequences preced-
ing a PAM (Mali et al. 2013). The conformational change induced by the binding of Cas9 to 
gRNA, the protospacer target DNA and PAM combined lead to activation of Cas9 nuclease 
domains and thus induce cleavage. In this case, both nuclease domains are active sites of a 
single protein, Cas9, and no dimerization is therefore necessary as is the case with TALEs 
and ZFs fused to FokI nuclease domains. According to Jinek et al., Cas9 is auto-inhibitory 
in its unbound state, which is corroborated by their x-ray crystallography structure data on 
unbound apo forms of SpyCas9 and AnaCas9 (Jinek et al. 2014). Sternberg et al. emphasize 
the role of PAM and propose the theory that it acts as an allosteric regulator of the nuclease 
activity of the Cas9-gRNA complex (Sternberg et al. 2014). This generates a potential risk 
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of off-target cleavage within PAM-rich regions of the genome, since PAM-Cas9 interaction 
is implied in destabilizing the structure and exposing the protospacer. Since the Cas9-gR-
NA complex displays very low binding affinity to a sequence that is complementary to the 
gRNA but lacks an adjacent PAM sequence, the fact that the CRISPR/Cas system relies on 
a shorter recognition sequence as opposed to ZFNs and TALENs might not turn out to be a 
major factor in relation to off-target cleavage. An interesting approach to mitigate off-target 
effects of the CRISPR/Cas system and at the same time retain the advantage of the flex-
ible RNA-guided binding mechanism has been explored recently: Tsai et al. attempted to 
construct dimeric RNA-guided FokI nucleases (RFNs) that combine the RNA-based DNA 
recognition domain of Cas9 with the FokI nuclease domain used by ZFNs and TALENs to 
allow for a more stringent control over DNA cleavage (Tsai et al. 2014).
Off-target effects along with toxicity and other adverse effects resulting from introduc-
ing the programmable endonucleases into cells could be partly attributed to the method of 
delivery. There are several methods available, using plasmid or viral vectors carrying the 
genes encoding the respective pair of ZFNs or TALENs, via lipofection, electroporation 
or microinjection. Each delivery method has its advantages and specificities, rendering it 
applicable in one case and unsuccessful in another. For example, lentiviral vectors as a 
means to deliver TALENs into cells have failed to perform as well as adenoviral vectors in 
one study (Holkers et al. 2013). Not every cell type is suitable for the introduction of DNA 
with the aforementioned methods, and the presence of foreign DNA within the cell can 
have adverse side-effects such as increased off-target effects due to random integration of 
the introduced DNA into the genome. This can be countered by introducing the nucleases 
in the form of  in vitro prepared mRNA, or avoiding nucleic acids entirely and introducing 
purified proteins directly (Gaj et al. 2012). The necessity to prepare mRNA or purify pro-
teins however carries its own specific disadvantages (such as the increased care necessary 
to avoid RNA degradation prior to delivery), and the limitations of available delivery sys-
tems are a major factor in restricting the use of all three described types of programmable 
endonucleases.
5.3 Multiplex genome engineering
Modifying two or more loci within the genome of one single organism has the potential 
to provide insight into gene interaction and redundancy in respect to function. Instead of 
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crossing specimen carrying a single mutation each in order to obtain the desired genotype, 
multiplex genome engineering allows for both loci to be modified simultaneously in one 
organism and thus eliminates the necessity for laborious and time-consuming breeding. 
Here, the architecture of the CRISPR/Cas system seems to be the most advantageous, since 
unlike ZFNs and TALENs, which require a pair of enzymes for every targeted locus, Cas9 
is a single enzyme that can be supplied with a variety of guide RNAs (gRNAs) that medi-
ate targeted cleavage at several loci simultaneously. Cong et al. have successfully used two 
gRNAs targeting two protospacers situated close to each other, which led to excision of the 
protospacer-flanked segment in-between (Cong et al. 2013). Multiple independent genome 
loci have been targeted simultaneously by using Cas9 in combination with several gRNAs 
in the zebrafish by Jao et al. and in the monkey Macaca fascicularis by Niu et al. (Jao et al. 
2013, Niu et al. 2014).
6. Examples of current and possible future applications
The emergence and subsequent development of programmable endonucleases has 
greatly impacted several fields: Zinc-finger nucleases (ZFNs) and their potential as genome 
editing tools have contributed to the mouse being established as the most widely used com-
plex eukaryote animal model. TALENs and the CRISPR/Cas system are offering new pos-
sibilities as a faster and more affordable means to generate genetically modified mouse 
strains, but their increased efficiency has had a far greater impact by allowing researchers 
to produce previously unattainable genetically engineered specimen of a vast variety of 
animal and plant species. Biotechnology can profit from employing programmable nucle-
ases as a means to genetically alter economically relevant livestock and crops, and there is 
potential for clinical application of highly precise programmable nucleases in gene therapy.
6.1 Mouse genome editing
Mouse genetics in particular is profiting from the opportunities offered by program-
mable endonucleases. The mouse is a widely used model organism, with many applications 
spanning basic research to biomedicine. The mouse genome was sequenced in 2002, and 
today many transgenic and knock-out strains are available to researchers (Chinwalla et 
al. 2002). To provide insight into gene function, two international initiatives have been 
launched with the aim of providing a repository of mouse strains harboring mutations in 
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every gene — the Knock-Out Mouse Project KOMP (Austin et al. 2004) and European Con-
ditional Mouse Mutagenesis EUCOMM (Auwerx et al. 2004).
A significant fraction of currently available genetically modified mouse strains have 
been created via modifying embryonic stem cells (ESCs) and pronuclear injection of DNA 
into zygotes (Glaser et al. 2005). In order to establish a homozygous strain carrying the 
desired mutation, ESCs that have been modified via transfection, electroporation or micro-
injection of a suitable DNA construct are added to blastocysts which are then transferred 
surrogate mothers producing chimeric offspring in the first generation. Through back-
crossing a suitable founder that produces gametes carrying the mutation, a stable strain 
can be established. The alternative method consists of modifying zygotes by microinjecting 
the DNA construct into the male pronucleus (Ittner and Götz 2007). Both methods heavily 
rely on the mechanism of homologous recombination (HR) as means to alter the recipient 
genome and therefore have been held back by the low frequency with which HR occurs 
naturally. Since the introduction of a double-strand break significantly increases the HR 
frequency, the use of programmable endonucleases is having a great impact on mouse ge-
nome engineering. Whereas five years ago, establishing a strain could take several years, 
now biallelic founders carrying the desired mutations can be obtained within weeks (Ma-
shiko et al. 2013).
Double knock-out mouse models have generally been obtained by crossing single 
knock-out strains with the desired mutation — a strategy that is very difficult to implement 
in the case of both genes being situated on the same chromosome. Due to infrequent cross-
ing-over events, it is possible to obtain offspring carrying both mutations in a large enough 
cohort. If the distance between the genes is too small to warrant a high enough crossing-
over frequency however, this strategy cannot be used — an alternative path is being made 
possible by employing TALENs and the CRISPR/Cas system as a means to induce both mu-
tations simultaneously, relying on their high efficiency. Thus, new previously unattainable 
mouse models could be generated utilising highly effective programmable endonucleases 
for multiplex genome engineering. 
Another interesting possibility programmable nucleases offer in this respect is target-
ed transgenesis (DeKelver et al. 2010). The introduction of exogenous genes into selected 
cell lines or organisms is a laborious process largely due to low efficiency when relying on 
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introducing the transgene randomly into the genome. Perez-Pinera et al. have engineered 
ZFNs targeting a well-studied mouse safe-harbor locus, ROSA26 (Perez-Pinera et al. 2012). 
Integration of a transgene into this locus ensures its ubiquitous expression over most tis-
sues and cell types and prevents disruption of an endogenous pathway. By using ZFNs to 
introduce DSBs within the ROSA26 locus and co-transfecting the cells with a vector con-
taining a multiple-cloning site (MCS) flanked by 800 bp fragments that were homologous 
to the sequences flanking the ZFN target site, Perez-Piera et al. have greatly increased the 
frequency of homologous recombination (HR), leading to integration of the MCS into the 
ROSA26 locus. They further showed that if an expression cassette containing EGFP fused 
to Zeomycin resistance was inserted into the MCS of the vector, it could be introduced into 
the ROSA26 locus this way. The yield of positive transgenic cells has been assayed by Perez-
Piera et al. using flow cytometry and estimated at 10%. TALENs and the CRISPR/Cas sys-
tem could be used in to facilitate gene targeting into safe-harbor loci in a similar fashion.
6.2 Generation of novel genetically modified organisms
Programmable endonucleases have not only been successfully used in a vast variety of 
model organisms such as mouse, rat, fruit fly and zebrafish, but also in economically rel-
evant crops and livestock including rice, maize, tobacco, and pig, displaying potential not 
only in basic research but also applied biotechnology (Urnov et al. 2010, Gaj et al. 2013, Sun 
and Zhao 2013). The number of species successfully targeted with programmable endonu-
cleases is rapidly increasing, with new species and new genes being added to the repertoire. 
To a large extent, programmable endonucleases are what drives this increase.
One of the reasons why the mouse has become such a widely used model organism is 
due to the availability of mouse embryonic stem cells (ESCs) in vitro, and the fact that these 
can be induced to mature into cell-culture derived animals (Nagy et al. 1993). This allowed 
for generating genetically modified mouse strains from ESCs, but restricted the method 
to only those species from which ESCs can be cultured and induced to mature into fully 
developed animals. With the development of programmable endonucleases however, an 
alternative has emerged in the form of directly modifying zygotes via DNA microinjection 
as a way to introduce mutations with high efficiency, thus removing the necessity of cultur-
ing and modifying ESCs. A notable breakthrough is the generation of targeted knock-out 
rats using ZFNs (Geurts et al. 2009). Rats are better suited than mice for several research 
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applications, not only due to their larger size, but also due to their highly developed cogni-
tive abilities — a notable example of a field that could greatly benefit from the availability 
of transgenic rat strains is neurobiology and optogenetics (Zalocusky and Deisseroth 2013).
One of the most recent additions to the compendium of successfully genetically modified 
species using programmable endonucleases is the cynomolgus monkey, Macaca fascicula-
ris — monkeys have resisted the use of both ZFNs and TALENs as means to induce genetic 
modifications, but Niu et al. report to have successfully introduced mutations in two genes 
(Ppar-γ and Rag1) by co-injecting Cas9 mRNA with gRNA targeting several genes into 
fertilized eggs (Niu et al. 2014). Another economically relevant organism that was recently 
successfully targeted with TALENs is the silkworm, the primary producer of silk (Takasu 
et al. 2013).
6.3 Gene therapy and other biomedical applications
Recently, a library of TALENs that target protein-coding genes within the human ge-
nome has been assembled (Kim et al. 2013). Kim et al. screened for suitable target sites 
within these genes and assembled 18740 plasmids carrying corresponding TALENs using 
a modified high-throughput Golden Gate assembly method. The success rate of the as-
sembled TALENs in a pilot study on HEK293 cells was 101 out of 103 target sites, with an 
average mutation frequency of 16%. There was a high variability in respect to performance, 
with the best performing TALEN pair displaying a mutation frequency of 54%. The fact 
that Kim et al. identified the two unsuccessfully targeted sites as having a high prevalence 
of methylated CpG islands suggests that factors such as methylation, DNA conformation 
and chromatin structure could play a role in influencing TALEN performance. The authors 
argue that in conjunction with a suitable screening assay for selecting successfully targeted 
cells, this TALEN library could be used to prepare knock-out cell lines that would provide 
more reliable insight into gene function than knock-down RNAi with its relatively high off-
target rate and reproducibility issues.
This study may aid in another field in which readily available highly specific pro-
grammable endonucleases could be expected to make an impact: gene therapy. Both 
ZFNs (Lombardo et al. 2011), and recently TALENs and the CRISPR/Cas system  have 
already been used as a genome editing tool on human induced and embryonic pluripo-
tent stem cells with varying degrees of success (Li et al. 2014). For utilizing their po-
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tential in biomedical and clinical applications, a much more stringent assessment 
of off-target mutations and cytotoxic effects of each respective nuclease is crucial. 
 The relative ease of controlled assembly of both TALENs and the CRISPR/Cas system 
opens up another interesting path that may lead to clinical applications in the future — 
the potential of programmable nucleases as a tool to correct genetic disease (Schwank 
et al. 2013). Wu et al. demonstrate that it is possible to rescue the phenotype dominant 
cataract disorder in mice, by injecting Cas9 mRNA along with gRNA targeting the deficient 
locus within the Cryc gene responsible for the disorder into zygotes that were obtained 
by crossing wild-type females with homozygous males carrying the Cryc gene mutation 
(Wu et al. 2013).  
7. Discussion
There is high variability in the nuclease-induced mutation frequencies reported in lit-
erature, but it is safe to say that TALENs surpass ZFNs in terms of efficiency, especially 
if the ease and speed with which they can be designed is taken into account. Their big-
gest advantage and potential lies in their accessibility, enabling their use in laboratories 
with access to basic molecular biology tools and with a limited budget to successfully em-
ploy TALENs in their research. In order to allow researchers to determine which system 
is the most suitable to be used in their respective setting though, it is crucial to uncover 
the mechanism and therefore the reasons behind off-target cleavage and the kind of vari-
ability in respect to activity reported by Kim et al. in their TALEN library. Kim et al. have 
successfully uncovered that CpG methylation can impair TALEN activity, but this accounts 
only for a fraction of the variability of activity displayed by the TALENs in their pilot study. 
Heterochromatin structure, DNA secondary structure, histone acetylation, method of de-
livery into the cell and a myriad other unexpected factors could play a significant role in 
influencing not only TALEN performance, but the performance of the CRISPR/Cas system 
as well. The same can be said about factors influencing their off-target activity and toxic-
ity, elimination of which is a crucial step towards clinical applications of programmable 
nucleases. Since both ZFNs and TALENs rely on a peptide-nucleotide bond when recogniz-
ing their cleavage target and the CRISPR/Cas system relies RNA-DNA bonding, it is safe 
to assume that their performance and vulnerability to certain conditions will reflect this 
difference.   
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Large-scale comparative studies that could offer more insight into these issues and aid 
further development would greatly benefit from improving the use of programmable endo-
nucleases in cell culture, a field that has somewhat lagged behind their use as a means to 
produce genetically modified organisms. Efficiency of cleavage varies greatly between cell 
types and to obtain cells that have been successfully edited requires labor-intensive culti-
vation of many clonal colonies and subsequent screening for mutations. There are several 
ways currently used to assess TALEN and CRISPR/Cas activity, notably the T7E1 assay 
which relies on PCR amplification from both wild-type DNA and DNA from the targeted 
cells, subsequent hybridization and heteroduplex cleavage (Niu et al. 2014). The drawbacks 
of using the T7E1 assay in cell culture screening is the need to isolate and amplify the DNA, 
which has to be preceded by generation of clonal colonies. Another strategy to screen for 
successful targeting is cotransfection of a reporter plasmid along with the ZFNs, TALENs 
or Cas9 and gRNA. The reporter plasmid that Kim et al. employ has a copy of the target 
sequences for both TALENs inserted into an mRFP-EGFP fusion expression cassette be-
tween mRFP and EGFP so that in its default state, EGFP is out of frame and thus only 
mRFP is expressed (Kim et al. 2011). If the nuclease is active within the cell, it cleaves its 
target on both chromosomal DNA and reporter plasmid, and reconstitutes EGFP expres-
sion in some cases where NHEJ leads to frameshift-inducing indels. Mashiko et al. use a 
similar reporter plasmid that relies on HR to restore EGFP expression as a result of nucle-
ase activity (Mashiko et al. 2013). We are currently working on improving on these con-
cepts by preparing a series of reporter plasmids that enable direct selection of successfully 
targeted cells from cell culture that can be used in conjunction with both TALENs and the 
CRISPR/Cas system.
8. Conclusion
Zinc-finger nucleases have been studied and used as a genome editing tool for several 
decades now, whereas the mechanism and function of TALE nucleases has been uncovered 
relatively recently. TALENs have greatly benefited from the volume of research in respect 
to performance, off-target activity, and mechanism that has already been done on ZFNs 
due to the fact that both systems use the same FokI nuclease domain. The functionally dif-
ferent CRISPR/Cas system however has been adapted as a genome editing tool only two 
years ago and is currently undergoing a surge of popularity (Shen 2013), even though there 
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is still relatively little insight into the mechanism underlying its function. This is being 
swiftly remedied as there is great interest to develop the method further. It is safe to say 
that both TALENs and the CRISPR/Cas system have not yet reached their full potential, 
despite the considerable impact their emergence has had in the few years since their dis-
covery and deployment as genome editing tools.
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